1. A. Gunduz, S. Turedi, A. Mentese, V. Altunayoglu, I. Turan, S.C. Karahan, M. Topbas, M. Aydin, I. Eraydin, B. Akcan, Ischemia-modified albumin levels in cerebrovascular accidents. Am. J. Emerg. Med. 26, 874–878 (2008)
2. S.G. Ma, W. Xu, C.L. Wei, X.J. Wu, B. Hong, Z.J. Wang, H.R. Hao, H.Q. Guo, Role of ischemia-modified albumin and total homocysteine in estimating symptomatic lacunar infarction in type 2 diabetic patients. Clin. Biochem. 44, 1299–1303 (2011)
3. S. Turedi, O. Cinar, I. Yavuz, A. Mentese, A. Gunduz, S.C. Karahan, M. Topbas, E. Cevik, A.O. Yildirim, A. Uzun, U. Kaldirim, Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J. Nephrol. 23, 335–340 (2010)
4. C.Y. Chen, W.L. Tsai, P.J. Lin, S.C. Shiesh, The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin. Chem. Lab. Med. 49, 1817–1821 (2011)
5. S.G. Ma, C.L. Wei, B. Hong, W.N. Yu, Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo). 66, 1677–1680 (2011)